CSL : Half Year Results Investor Presentation

For personal use only

For immediate release

16 February 2022

RESULTS PRESENTATION

FOR THE HALF YEAR ENDED 31 DECEMBER 2021

Melbourne, Australia - CSL (ASX:CSL; USOTC:CSLLY)

Please find attached the slides for the presentation on the half year results that will be given by the Chief Executive Officer and the Chief Financial Officer shortly.

The briefing will be webcast and can be accessed in the "Investor" section of CSL's website (www.CSL.com).

Authorised for lodgment by:

Fiona Mead

Company Secretary

For further information, please contact:

Investors:	Media:
Bernard Ronchi	Jimmy Baker
Investor Relations	Communications
CSL Limited	CSL Limited
P: [phone]	P: [phone]
E: [e-mail]	E: [e-mail]

ersonal use only

CSL Limited

2022 Half Year Results

16 February, 2022

Paul Perreault	Joy Linton
CEO and Managing Director	CFO

ersonal use only

2

Legal Notice

IMPORTANT NOTICE AND DISCLAIMER

This presentation contains summary information about CSL Limited (ACN 004 089 936) and its related bodies corporate (together, CSL) and CSL's activities as at the date of this presentation. It is information given in summary form only and does not purport to be complete. It should be read in conjunction with CSL's other periodic corporate reports and continuous disclosure announcements filed with the Australian Securities Exchange (ASX), available at www.asx.com.auThis presentation is for information purposes only and is not a prospectus or product disclosure statement, financial product or investment advice or a recommendation to acquire CSL shares or other securities.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of CSL or its directors, employees or agents, nor any other person, accepts liability for any loss arising from the use of this presentation or its contents or otherwise arising in connection with it, including, without limitation, any liability from fault or negligence on the part of CSL or its directors, employees, contractors or agents.

This presentation contains forward-looking statements in relation to CSL, including statements regarding CSL's intent, belief, goals, objectives, initiatives, commitments or current expectations with respect to CSL's business and operations, market conditions, results of operations and financial conditions, products in research and risk management practices. Forward-looking statements can generally be identified by the use of words such as "forecast", "estimate", "plan", "will", "anticipate", "may", "believe", "should", "expect", "project," "intend", "outlook", "target", "assume" and "guidance" and other similar expressions.

The forward-looking statements are based on CSL's good faith assumptions as to the financial, market, risk, regulatory and other relevant environments that will exist and affect CSL's business and operations in the future. CSL does not give any assurance that the assumptions will prove to be correct. The forward-looking statements involve known and unknown risks, uncertainties and assumptions and other important factors, many of which are beyond the control of CSL, that could cause the actual results, performances or achievements of CSL to be materially different to future results, performances or achievements expressed or implied by the statements. . Factors that could cause actual results to differ materially include: the success of research and development activities, decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; competitive developments affecting our products; the ability to successfully market new and existing products; difficulties or delays in manufacturing; trade buying patterns and fluctuations in interest and currency exchange rates; legislation or regulations that affect product production, distribution, pricing, reimbursement, access or tax; acquisitions or divestitures; research collaborations; litigation or government investigations, and CSL's ability to protect its patents and other intellectual property.

Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as at the date of the presentation. Except as required by applicable laws or regulations, CSL does not undertake any obligation to publicly update or revise any of the forward-looking statements or to advise of any change in assumptions on which any such statement is based.

TRADEMARKS

Except where otherwise noted, brand names designated by a ™ or ® throughout this presentation are trademarks either owned by and/or licensed to CSL.

ersonal use only

CEO Overview

Paul Perreault

CEO & Managing Director

1H22 Performance1

Revenue up 4% with net profit after tax down 5%

ersonal use only

CSL has performed

in line with expectations

As expected Ig & Albumin sales have been limited by COVID constrained plasma collections in FY21

Plasma collections have been

returning and expected to underpin

future sales growth

Strong performance by key

specialty products and Idelvion

Agreement to acquire

Vifor Pharma Ltd

CSL Behring

• IDELVION® +17%
• KCENTRA® +15%
• HAEGARDA® +7%
• HPV royalties +134%
• Immunoglobulin -9%
• 18 new collection centres opened
• Continued investment into digital transformational tools

Seqirus

• Seasonal influenza vaccines +20%
• Record volume of ~110 million doses distributed NH 21/22
• Continued benefits of differentiated products
• FLUCELVAX® Quadrivalent:
• • US and Argentina approval 6M+ indication
• Commenced construction on new cell culture influenza vaccine manufacturing facility

4

1. Growth percentages shown at constant currency to remove the impact of exchange rate movements, facilitating comparability of operational performance. See end note for further detail.